Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: An updated meta-analysis

Coronary Artery Disease

Volumn 25, Issue 5, 2014, Pages 369-377

  Li, Peng ^a   Liu, Jun Peng ^b  

^a PEKING UNIVERSITY SHOUGANG HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

diabetes; everolimus eluting stent; major adverse cardiac event; paclitaxel eluting stent; very late stent thrombosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; CARDIOVASCULAR AGENT; RAPAMYCIN;

ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; RISK ASSESSMENT; STENT THROMBOSIS; ADVERSE EFFECTS; AGE; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; COMORBIDITY; CORONARY THROMBOSIS; DEVICES; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGE FACTORS; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; ODDS RATIO; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904037853     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000109     Document Type: Article

References (30)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368:254-265.
2. Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5:357-364.
3. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379:1393-1402.
4. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435-2441.
5. Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, et al. Percutaneous coronary intervention with second-generation paclitaxeleluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial). Am J Cardiol 2012; 110:1119-1124.
6. De la Torre Hernandez JM, Alfonso F, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, Hernandez F, et al. Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry). Am J Cardiol 2013; 111:676-683.
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62:1006-1012.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
10. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323:42-46.
11. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, et al. 2-year follow-up of a randomized controlled trial of everolimus-and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol 2011; 58:11-18.
12. Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012; 163:867-875.
13. Kim U, Lee CH, Jo JH, Lee HW, Choi YJ, Son JW, et al. A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study. J Korean Med Sci 2013; 28:1609-1614.
14. Onuma Y, Miquel-Hebert K, Serruys PW. Five-year long-term clinical followup of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: The SPIRIT II trial. EuroIntervention 2013; 8:1047-1051.
15. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J 2013; 166:1035-1042.
16. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS Paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 2013; 6:1263-1266.
17. Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, et al. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). JACC Cardiovasc Interv 2013; 6:1012-1022.
18. Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo KK, Wong SC, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012; 5:131-140.
19. Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis 2012; 2012:126369.
20. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873-2891.
21. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013; 347:f6530.
22. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62:496-504.
23. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6:914-922.
24. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347:f6625.
25. Johnman C, Oldroyd KG, Mackay DF, Slack R, Pell AC, Flapan AD, et al. Percutaneous coronary intervention in the elderly: changes in case-mix and periprocedural outcomes in 31758 patients treated between 2000 and 2007. Circ Cardiovasc Interv 2010; 3:341-345.
26. Qin SY, Zhou Y, Jiang HX, Hu BL, Tao L, Xie MZ. The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One 2013; 8:e72710.
27. Hermiller JB, Sudhir K, Applegate RJ, Rizvi A, Wang J, Gordon PC, et al. Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention 2012; 8:87-93.
28. Shammas NW, Shammas GA, Sharis P, Jerin M. Age differences in long term outcomes of coronary patients treated with drug eluting stents at a tertiary medical center. J Aging Res 2013; 2013:1-4.
29. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011; 4:1057-1066.
30. Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009; 124:46-51.